• Celcuity Inc. recently expanded its Phase 3 VIKTORIA-2 trial of gedatolisib for advanced HR+/HER2- breast cancer and filed a U.S. patent application for a subcutaneous formulation, following a Type B meeting with the FDA.
• By broadening VIKTORIA-2 to both endocrine-resistant and endocrine-sensitive patients and pursuing an injection-based version of gedatolisib, Celcuity is refining how its lead therapy could be used across more real-world treatment settings.
• We’ll now examine how expanding VIKTORIA-2 to endocrine-sensitive patients and pursuing a subcutaneous formulation may reshape Celcuity’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Celcuity Investment Narrative Recap

To own Celcuity, you have to believe gedatolisib can convert strong late stage data into an approved, widely used therapy in HR+/HER2- advanced breast cancer while the company manages years of losses with no current product revenue. The key near term catalyst remains FDA review and potential launch in second line disease, with VIKTORIA 2 progress a close second. The latest VIKTORIA 2 expansion and subcutaneous work refine the story but do not alter that central trade off.

Among recent announcements, Celcuity’s Q1 2026 results highlight the financial side of that trade: a net loss of US$52.84 million and basic loss per share of US$0.97. For investors tracking the larger Phase 3 program and the move into first line settings, this sustained cash burn is an important backdrop to the expanded VIKTORIA 2 trial, the subcutaneous formulation plans and any future financing needs that might follow.

But while the trial expansion is encouraging, investors should also be aware that...

Celcuity's narrative projects $607.1 million revenue and $152.4 million earnings by 2029. This implies an earnings increase of about $315 million from -$162.7 million today.

Uncover how Celcuity's forecasts yield a $116.70 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were, before this update, modeling about US$1.3 billion of revenue and roughly US$459 million of earnings by 2029, which is a far more upbeat path than consensus. As you weigh this new VIKTORIA 2 design and the extended breast cancer ambitions against that outlook, it is worth asking whether those bullish expectations still fit your own view of what comes next.

Explore 3 other fair value estimates on Celcuity - why the stock might be worth over 6x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Celcuity research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.